- Tuesday, December 23, 2025
- India +91 7982732466
- U.S +1 217 953 4020
- Info@Shingetsuresearch.com
Global AI-Enabled Drug Discovery and Clinical Trials Market
- March 28, 2020
- ID: SR/HC-13
- Format:Pdf
- Pages:220
Global AI-Enabled Drug Discovery and Clinical Trials Market by Component (Solutions and Services), By Solution (Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, Biomarker Research and Others), By Therapeutic Applications (Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Disorder, Metabolic Diseases, Immunologic Diseases, Infectious Diseases and Others), By End-User(Biopharmaceutical Industry, Contract Research Organizations (CROs), and Academic Institutes and Research Centers), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), Forecast to 2022 to 2030.
Description
Global AI-Enabled Drug Discovery and Clinical Trials Market Overview
Global AI-Enabled Drug Discovery and Clinical Trials Market is estimated to reach USD 19.4 billion by 2030, growing at a CAGR of 30.8% during the forecast period of 2022-2030. It was valued at USD 1.5 billion in 2022. The use of artificial intelligence (AI) technology can improve research and development efficiency and reduce cost investment to a certain extent. The design, discovery, and development of new drugs will also be shortened. The use of AI is to develop new drugs as it simulates the process of drug screening by computer, to predict the activity of compounds, and to conduct targeted physical screening of potential compounds. AI in the pharmaceutical industry mainly plays a supporting role, including drug mining, in-depth learning algorithm analysis of data, and prediction of new drug effectiveness, etc., to a certain extent, improve the efficiency of research and development, save money and reduce the risk of clinical trial failure. AI uses big data and machine learning methods to propose the structural characteristics of drug targets and small molecule drugs from a large amount of information in papers, patents, and clinical experiments.Global AI-Enabled Drug Discovery and Clinical Trials Market Insights
The rise in demand for artificial intelligence to control drug discovery & development costs and reduce the overall time taken in this process would accelerate the growth of AI-enabled drug discovery and clinical trials market. Moreover, the growing application of AI to generate novel drug candidate, and aggregate and synthesize information will expand the AI-enabled drug discovery industry in the next few years. Additionally, AI in clinical trials improve the effectiveness of clinical trials and reduce cost, such as identifying the right classification of humans based on genomics, which leads to triggering the global AI-enabled clinical trials market in the future periods. Artificial intelligence used to capture clinical data from multiple internal data sources to predict and monitor patient recruitment, cost, and quality of clinical trials. Also, the application of artificial intelligence technology in all stages of drug development: including deep feature selection, NLP in the target discovery stage; deep learning in the generation of new small molecule lead compounds; and clinical research on small molecules. Furthermore, the AI helping the drug industry by storing, manage, and trade life data: social network data, health data, and medical records.Growth Driver
Increasing Adoption of Artificial Intelligence and Machine Learning in Drug Discovery and Clinical Trials Industry
The Artificial Intelligence has developed to assist the drug discovery industry, in several ways: predicting the outcome of a reaction with a given set of lead compounds, predicting the yield of a chemical reaction, and reverse-synthesizing planning. With the increase in computing power, AI will be able to introduce new treatments to the market at a much lower cost and at an amazing speed, without the need for large-scale infrastructure and investment. AI enables us to produce complex multi-targeted drugs, enabling one drug to treat multiple diseases. AI has the potential to automatically find meaning patterns in large data sets, such as text, speech, or images. Natural language processing (NLP) can understand and correlate written or spoken language and the content of the human-machine interface (HMI), allowing natural information exchange between computers and humans.Components Segmental Analysis
Based on components, the global AI-enabled drug discovery and clinical trials market bifurcated into Solutions and Services. The solutions segment predicted to gain a major share in the market by 2030, owing to the AI reduce timelines for drug discovery and improve the agility of the research process and surge the accuracy of predictions on the efficacy and safety of drugs. The services segment will grow attributable to accelerate patient recruitment and identify patients who match complex trial criteria in minutes.Solution Segmental Analysis
Based on the Solution, the global AI-Enabled drug discovery and clinical trials market classified into Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, Biomarker Research, and Others. The Drug Design segment projected to register higher CAGR due to the AI helps companies to build capability, which mixes human expertise with an understanding of data and technology and secure buy-in and ensure these are used correctly. The Clinical Trials segment will influence owing to the benefits of AI, such as improving data quality, increasing patient compliance & retention, and identifying treatment efficacy more efficiently and reliably than ever before.Application Segmental Analysis
Based on application, the global AI-Enabled Drug Discovery and Clinical Trials market classified into Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Disorder, Metabolic Diseases Immunologic Diseases, Infectious Diseases, and Others. The Oncology segment estimated to generate maximum revenue by 2030, as AI is helpful for cancer treatment such as Cancer Imaging, identify optimal treatments, enabling early diagnosis and interventions, and enable faster development of life-saving drugs. The security & Surveillance segment will grow by the benefits of AI, such as clinicians diagnose disease and optimize treatment processes.End-User Segmental Analysis
Based on end-user, the global AI-enabled drug discovery and clinical trials market categorized into Biopharmaceutical Industry, Contract Research Organizations (CROs), and Academic Institutes and Research Centers. Biopharmaceutical Industry segment expected to lead the market on account of the AI help in developing new drugs, predict untested components researchers should explore to find new cures and automated data gathering and analysis to create solutions to some of the most complex diseases. The industrial segment will drive by application of AI, which helps in finding better clinical trials.Region Segmental Analysis
Based on geography, the global AI-Enabled Drug Discovery and Clinical Trials market segmented into North America, Asia Pacific, Europe, South America, and Middle East & Africa. North America estimated to occupy the lion’s market share by 2030, owing to the growing demand for AI in the medical, healthcare system, and pharma sector, coupled with the USA government spending more budget on health systems. The Asia Pacific will drive by the surge in chronic diseases coupled the developing countries like China and India, giving financial support to the healthcare industry.Competitor Analysis
Companies such as Accutar Biotechnology Inc., AiCure, LLC, Ardigen, Atomwise, Inc, BenevolentAI, Berg LLC, Berkeley Lights, Inc., BioAge Labs, Inc., C4X Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., Cyclica, Inc., CytoReason, and Symphony Innovation, LLC are the key players in the Global AI-Enabled Drug Discovery and Clinical Trials Market.Key Stakeholders
- Market research and consulting firms
- Industry associations
- Global AI-Enabled Drug Discovery and Clinical Trials providing firms
- Research organizations and consulting companies
- Organizations, associations, and alliances related to AI-Enabled Drug Discovery and Clinical Trials
- Regulatory bodies
Scope of the report
| Report Attribute | Details |
|---|---|
| Market size value in 2020 | USD 370 million |
| Revenue forecast in 2027 | USD 2925 million |
| Growth Rate | CAGR of 38.65% from 2020 to 2027 |
| Historical data | 2017-2019 |
| Forecast period | 2021 – 2027 |
| Region covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Key companies Profiled | Accutar Biotechnology Inc., BioAge Labs, Inc., C4X Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., AiCure, LLC, Ardigen, Atomwise, Inc, BenevolentAI, Berg LLC, Berkeley Lights, Inc., Cyclica, Inc., CytoReason, and Symphony Innovation, LLC |
Recent Developments
- In September 2021, Owkin partnered with Actelion Pharmaceuticals Ltd. to manufacture innovative methods with the potential to augment AI-enabled external control arms.
- In September 2021, Swift Medical’s launched Swift Scientific to expand the digital wound care company into decentralized trials.
- In September 2021, Sensyne Health signed a non-exclusive strategic research agreement with Great Ormond Street Hospital for Children (GOSH) to drive research into childhood disease through ethical AI applications.
The objective of the Research
- Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
- Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
- Market Trend and Economic Factors Analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
- Market Segmental Analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics
- The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.
Market Modelling
By Component- Solution
- Services
- Data Aggregation and Analysis
- Clinical Trials
- Drug Design
- Drug Characterization
- Biomarker Research
- Others
- Oncology
- Cardiovascular Diseases
- Nervous System Diseases
- Respiratory Disorder
- Metabolic Diseases
- Immunologic Diseases
- Infectious Diseases
- Others
- Biopharmaceutical Industry
- Contract Research Organizations (CROs)
- Academic Institutes and Research Centers
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
More Related Reports:
Simultaneous Localization and Mapping Technology Market
Table Of Contents
Global AI-Enabled Drug Discovery and Clinical Trials Market
Report Content
- Research Strategic Development
- Market Modelling
- Product Analysis
- Market Trend and Economic Factors Analysis
- Market Segmental Analysis
- Geographical Mapping
- Country Wise Segregation
- Research Methodology
- Identification of Target Market
- Data Acquisition
- Refining of Data/ Data Transformations
- Data Validation through Primary Techniques
- Exploratory Data Analysis
- Graphical Techniques/Analysis
- Quantitative Techniques/Analysis
- Visual Result/Presentation
- Executive Summary
- Market Insights
- Economic Factor Analysis
- Drivers
- Trends
- Opportunities
- Challenges
- Technological Landscape
- Competitors & Product Analysis
- Regulatory Framework
- Company market share analysis, 2019
- Porter’s Five forces analysis
- New Investment Analysis
- PESTEL Analysis
- Economic Factor Analysis
- Global AI-Enabled Drug Discovery and Clinical Trials Market Overview
- Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Market Share & Forecast, 2016-2027
- By Component
- Solutions
- Services
- By Solution
- Data Aggregation and Analysis
- Clinical Trials
- Drug Design
- Drug Characterization
- Biomarker Research
- Others
- By Application
- Oncology
- Cardiovascular Diseases
- Nervous System Diseases
- Respiratory Disorder
- Metabolic Diseases
- Immunologic Diseases
- Infectious Diseases
- Others
- By End-User
- Biopharmaceutical Industry
- Contract Research Organizations (CROs)
- Academic Institutes and Research Centers
- By Region
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
- By Component
- Demand
- Market Size & Forecast, 2016-2027
- North America AI-Enabled Drug Discovery and Clinical Trials Market Overview
- North America AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- North America AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
- By Component
- Solutions
- Services
- By Solution
- Data Aggregation and Analysis
- Clinical Trials
- Drug Design
- Drug Characterization
- Biomarker Research
- Others
- By Application
- Oncology
- Cardiovascular Diseases
- Nervous System Diseases
- Respiratory Disorder
- Metabolic Diseases
- Immunologic Diseases
- Infectious Diseases
- Others
- By End-User
- Biopharmaceutical Industry
- Contract Research Organizations (CROs)
- Academic Institutes and Research Centers
- By Country
- US
- Canada
- Mexico
- Company Market Share (Top 3-5)
- Economic Impact Study on North America AI-Enabled Drug Discovery and Clinical Trials Market
- By Component
- Demand
- North America AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Europe AI-Enabled Drug Discovery and Clinical Trials Market Overview
- Europe AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Europe AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
- By Component
- Solutions
- Services
- By Solution
- Data Aggregation and Analysis
- Clinical Trials
- Drug Design
- Drug Characterization
- Biomarker Research
- Others
- By Application
- Oncology
- Cardiovascular Diseases
- Nervous System Diseases
- Respiratory Disorder
- Metabolic Diseases
- Immunologic Diseases
- Infectious Diseases
- Others
- By End-User
- Biopharmaceutical Industry
- Contract Research Organizations (CROs)
- Academic Institutes and Research Centers
- By Country
- Germany
- UK
- France
- Italy
- Rest of Europe
- Company Market Share (Top 3-5)
- Economic Impact Study on Europe AI-Enabled Drug Discovery and Clinical Trials Market
- By Component
- Demand
- Europe AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market Overview
- Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
- By Component
- Solutions
- Services
- By Solution
- Data Aggregation and Analysis
- Clinical Trials
- Drug Design
- Drug Characterization
- Biomarker Research
- Others
- By Application
- Oncology
- Cardiovascular Diseases
- Nervous System Diseases
- Respiratory Disorder
- Metabolic Diseases
- Immunologic Diseases
- Infectious Diseases
- Others
- By End-User
- Biopharmaceutical Industry
- Contract Research Organizations (CROs)
- Academic Institutes and Research Centers
- By Country
- China
- India
- Japan
- Australia
- Rest of Asia Pacific
- Company Market Share (Top 3-5)
- Economic Impact Study on Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market
- By Component
- Demand
- Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- South America AI-Enabled Drug Discovery and Clinical Trials Market Overview
- South America AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- South America AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
- By Component
- Solutions
- Services
- By Solution
- Data Aggregation and Analysis
- Clinical Trials
- Drug Design
- Drug Characterization
- Biomarker Research
- Others
- By Application
- Oncology
- Cardiovascular Diseases
- Nervous System Diseases
- Respiratory Disorder
- Metabolic Diseases
- Immunologic Diseases
- Infectious Diseases
- Others
- By End-User
- Biopharmaceutical Industry
- Contract Research Organizations (CROs)
- Academic Institutes and Research Centers
- By Country
- Brazil
- Argentina
- Rest of South America
- Company Market Share (Top 3-5)
- Economic Impact Study on South America AI-Enabled Drug Discovery and Clinical Trials Market
- By Component
- Demand
- South America AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market Overview
- Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
- By Component
- Solutions
- Services
- By Solution
- Data Aggregation and Analysis
- Clinical Trials
- Drug Design
- Drug Characterization
- Biomarker Research
- Others
- By Application
- Oncology
- Cardiovascular Diseases
- Nervous System Diseases
- Respiratory Disorder
- Metabolic Diseases
- Immunologic Diseases
- Infectious Diseases
- Others
- By End-User
- Biopharmaceutical Industry
- Contract Research Organizations (CROs)
- Academic Institutes and Research Centers
- By Country
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
- Company Market Share (Top 3-5)
- Economic Impact Study on Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market
- By Component
- Demand
- Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
- Competitor Analysis
- Company Description
- Financial Analysis
- Key Products
- Key Management Personnel
- Contact Address
- SWOT Analysis
- Company Profile
- Accutar Biotechnology Inc.
- AiCure, LLC
- Ardigen
- Atomwise, Inc
- BenevolentAI
- Berg LLC
- Berkeley Lights, Inc.
- BioAge Labs, Inc.
- Biovista Inc
- C4X Discovery Holdings Plc
- Clinithink Ltd
- Cloud Pharmaceuticals, Inc.
- Cyclica, Inc.
- CytoReason,
- Symphony Innovation, LLC
- Other Prominent Players
Methodology
Request Sample
Frequently Asked Questions (FAQ):
AI is used for drug discovery and clinical trials by predicting the 3D protein structure, collecting and analyzing Real World Data and developing novel patient-centered endpoints.
The rising use of Machine Learning and Artificial Intelligence and reduced cost investment are the growth drivers of the global AI-Enabled Drug Discovery and Clinical Trials, Market.
The growth rate of the Global AI-Enabled Drug Discovery and Clinical Trials Market is 30.8% from 2022 to 2030.
Global AI-Enabled Drug Discovery and Clinical Trials Market is estimated to reach USD 19.4 billion by 2030, and It was valued at USD 1.5 billion in 2022.
Accutar Biotechnology Inc., BioAge Labs, Inc., C4X Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., AiCure, LLC, Ardigen, Atomwise, Inc, BenevolentAI, Berg LLC, Berkeley Lights, Inc., Cyclica, Inc., CytoReason, and Symphony Innovation, LLC are the key players in the Global AI-Enabled Drug Discovery and Clinical Trials, Market.
